ONTARGET: After a three-week (+ 1 week) single-blind run-in period using both ramipril and telmisartan, to assess patient tolerability and compliance to study medications, patients will be randomized to one of the three double-blind treatment arms: telmisartan 80 mg plus ramipril placebo, ramipril 5 mg plus telmisartan placebo, or the combination of telmisartan 80 mg + ramipril 5 mg. 5606 high tor hill columbia md trial#TRANSCEND This parallel trial is to determine in ACE-I-intolerant patients if telmisartan 80 mg daily is superior to placebo in reducing the composite endpoint of cardiovascular death, MI, stroke or hospitalization for CHF. not less effective than) Ramipril 10 mg daily, on this endpoint. ONTARGET Primary objectives: To determine if (a) Telmisartan (Micardis) 80 mg daily and Ramipril (Delix protect) 10 mg daily combination therapy is more effective in reducing the composite endpoint of CV death, MI, stroke or hospitalization for CHF compared with Ramipril 10 mg alone and (b) Telmisartan 80 mg daily is at least as effective as (i.e. Outcome Measures, Baseline Characteristics, Participant Flow, Study Status and Adverse Events Outcome Measures, Eligibility, Study Description and Study StatusĪdverse Events, Study Status and ReferencesĬontacts/Locations, Study Status and References More Information, Outcome Measures and Study Status Outcome Measures, Study Status, More Information, Adverse Events, Baseline Characteristics, Participant Flow, Eligibility and Study Description Study Status, Outcome Measures, Results and Contacts/Locations Recruitment Status, Contacts/Locations, Study Status, Study Design, Outcome Measures, Study Identification, Eligibility, Arms and Interventions, Oversight and Sponsor/CollaboratorsĬontacts/Locations, Study Status, Eligibility, Arms and Interventions and Study Identification Outcome Measures, Study Status, Contacts/Locations, Eligibility, Arms and Interventions and Study Identification Study Status, Contacts/Locations and EligibilityĬontacts/Locations, Study Status, Outcome Measures, Eligibility and OversightĬontacts/Locations, Oversight and Study StatusĬontacts/Locations, Outcome Measures, Study Status, Eligibility and Arms and Interventions Study Design, Study Status, Contacts/Locations, Eligibility and Study Description Contacts/Locations, Study Identification and Study StatusĬontacts/Locations, Study Status and Study IdentificationĬontacts/Locations, Outcome Measures and Study StatusĬontacts/Locations, Study Status, Sponsor/Collaborators and Study IdentificationĬontacts/Locations, Study Status, Eligibility, Study Description, Oversight and Study Identification
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |